Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Org 26576 in Major Depressive Disorder
NCT00610649Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of Org 26576 in major depressive disorder (MDD) (11 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants With Moderate Intensity Adverse Events up to 23 days, Number of Participants With Serious Adverse Events up to 46 days and 2 more. Started Sep 2007; status: completed.
02
Drugs
Org 26576
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00610649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00610649.